Hematopoietic stem cell transplantation in autoimmune diseases: Algorithm for cardiovascular assessment

Irene Miniati, Maria Letizia Conforti, Pasquale Bernardo, Alan Tyndall, Gian Franco Gensini, Marco Matucci-Cerinic

Research output: Contribution to journalArticle

Abstract

Heart involvement is a frequent cause of morbidity and mortality in autoimmune diseases. All cardiac structures can be involved: pericardium, endocardium, myocardium, coronary circle, and conduction system. In the last decade many patients affected by autoimmune diseases have been treated with hematopoietic stem cell transplantation; the vast majority of these transplants have been autologous, and most have been within the context of phase I and II clinical trials; now, phase III trials are ongoing. Patients affected by autoimmune disease often have cardiac involvement which potentially puts them at higher risk from acute cardiotoxicity due to alkylating agents such as cyclophosphamide. The authors propose an algorithm for cardiac assessment before stem cell transplantation in order to identify those patients at highest risk, prior to administering any drug, to avoid further worsening of heart involvement and possible organ failure. A baseline assessment includes physical examinations, ECG to highlight arrhythmias and conduction abnormalities, chest X-ray to evaluate the presence of pericardial effusion and cardiothoracic ratio. A second-step evaluation includes echocardiography (which assesses the following parameters: left ventricular ejection fraction, diastolic function, tricuspid gradient, pulmonary acceleration time, right ventricular diameter and pericardial effusion, wall motion), Holter ECG that may highlight the presence of arrhythmias and biohumoral parameters such as brain natriuretic peptide and troponin I. If these parameters show abnormalities, a further step is required before transplantation. Cardiac catheterization allows to identify ischemic coronary diseases and pulmonary artery hypertension. Intensive monitoring with life card assessment before inclusion might establish ischemic coronary diseases or complex arrhythmias requiring pacing. Magnetic resonance imaging and single-photon emission computed tomography with dipyridamole are useful tools to evaluate the coronary flow. Treatment of ischemic coronary disease (assessment for revascularization), cardiac failure, pulmonary artery hypertension and arrhythmias constitutes the final step. The aim is to optimize cardiac status in order to allow intense immunosuppressive treatments.

Original languageEnglish
Pages (from-to)43-50
Number of pages8
JournalHerz
Volume32
Issue number1
DOIs
Publication statusPublished - Jan 2007

Fingerprint

Hematopoietic Stem Cell Transplantation
Autoimmune Diseases
Cardiac Arrhythmias
Coronary Disease
Pericardial Effusion
Pulmonary Hypertension
Pulmonary Artery
Electrocardiography
Endocardium
Phase II Clinical Trials
Clinical Trials, Phase I
Troponin I
Dipyridamole
Brain Natriuretic Peptide
Alkylating Agents
Pericardium
Stem Cell Transplantation
Immunosuppressive Agents
Cardiac Catheterization
Single-Photon Emission-Computed Tomography

Keywords

  • Cardiac assessment
  • Cardiotoxicity
  • Immunosuppressive drugs
  • Stem cell transplantation
  • Systemic sclerosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Miniati, I., Conforti, M. L., Bernardo, P., Tyndall, A., Gensini, G. F., & Matucci-Cerinic, M. (2007). Hematopoietic stem cell transplantation in autoimmune diseases: Algorithm for cardiovascular assessment. Herz, 32(1), 43-50. https://doi.org/10.1007/s00059-007-2957-4

Hematopoietic stem cell transplantation in autoimmune diseases : Algorithm for cardiovascular assessment. / Miniati, Irene; Conforti, Maria Letizia; Bernardo, Pasquale; Tyndall, Alan; Gensini, Gian Franco; Matucci-Cerinic, Marco.

In: Herz, Vol. 32, No. 1, 01.2007, p. 43-50.

Research output: Contribution to journalArticle

Miniati, I, Conforti, ML, Bernardo, P, Tyndall, A, Gensini, GF & Matucci-Cerinic, M 2007, 'Hematopoietic stem cell transplantation in autoimmune diseases: Algorithm for cardiovascular assessment', Herz, vol. 32, no. 1, pp. 43-50. https://doi.org/10.1007/s00059-007-2957-4
Miniati I, Conforti ML, Bernardo P, Tyndall A, Gensini GF, Matucci-Cerinic M. Hematopoietic stem cell transplantation in autoimmune diseases: Algorithm for cardiovascular assessment. Herz. 2007 Jan;32(1):43-50. https://doi.org/10.1007/s00059-007-2957-4
Miniati, Irene ; Conforti, Maria Letizia ; Bernardo, Pasquale ; Tyndall, Alan ; Gensini, Gian Franco ; Matucci-Cerinic, Marco. / Hematopoietic stem cell transplantation in autoimmune diseases : Algorithm for cardiovascular assessment. In: Herz. 2007 ; Vol. 32, No. 1. pp. 43-50.
@article{fbefa65b10a04d2397c8368c1eb9e57b,
title = "Hematopoietic stem cell transplantation in autoimmune diseases: Algorithm for cardiovascular assessment",
abstract = "Heart involvement is a frequent cause of morbidity and mortality in autoimmune diseases. All cardiac structures can be involved: pericardium, endocardium, myocardium, coronary circle, and conduction system. In the last decade many patients affected by autoimmune diseases have been treated with hematopoietic stem cell transplantation; the vast majority of these transplants have been autologous, and most have been within the context of phase I and II clinical trials; now, phase III trials are ongoing. Patients affected by autoimmune disease often have cardiac involvement which potentially puts them at higher risk from acute cardiotoxicity due to alkylating agents such as cyclophosphamide. The authors propose an algorithm for cardiac assessment before stem cell transplantation in order to identify those patients at highest risk, prior to administering any drug, to avoid further worsening of heart involvement and possible organ failure. A baseline assessment includes physical examinations, ECG to highlight arrhythmias and conduction abnormalities, chest X-ray to evaluate the presence of pericardial effusion and cardiothoracic ratio. A second-step evaluation includes echocardiography (which assesses the following parameters: left ventricular ejection fraction, diastolic function, tricuspid gradient, pulmonary acceleration time, right ventricular diameter and pericardial effusion, wall motion), Holter ECG that may highlight the presence of arrhythmias and biohumoral parameters such as brain natriuretic peptide and troponin I. If these parameters show abnormalities, a further step is required before transplantation. Cardiac catheterization allows to identify ischemic coronary diseases and pulmonary artery hypertension. Intensive monitoring with life card assessment before inclusion might establish ischemic coronary diseases or complex arrhythmias requiring pacing. Magnetic resonance imaging and single-photon emission computed tomography with dipyridamole are useful tools to evaluate the coronary flow. Treatment of ischemic coronary disease (assessment for revascularization), cardiac failure, pulmonary artery hypertension and arrhythmias constitutes the final step. The aim is to optimize cardiac status in order to allow intense immunosuppressive treatments.",
keywords = "Cardiac assessment, Cardiotoxicity, Immunosuppressive drugs, Stem cell transplantation, Systemic sclerosis",
author = "Irene Miniati and Conforti, {Maria Letizia} and Pasquale Bernardo and Alan Tyndall and Gensini, {Gian Franco} and Marco Matucci-Cerinic",
year = "2007",
month = "1",
doi = "10.1007/s00059-007-2957-4",
language = "English",
volume = "32",
pages = "43--50",
journal = "Herz",
issn = "0340-9937",
publisher = "Urban und Vogel",
number = "1",

}

TY - JOUR

T1 - Hematopoietic stem cell transplantation in autoimmune diseases

T2 - Algorithm for cardiovascular assessment

AU - Miniati, Irene

AU - Conforti, Maria Letizia

AU - Bernardo, Pasquale

AU - Tyndall, Alan

AU - Gensini, Gian Franco

AU - Matucci-Cerinic, Marco

PY - 2007/1

Y1 - 2007/1

N2 - Heart involvement is a frequent cause of morbidity and mortality in autoimmune diseases. All cardiac structures can be involved: pericardium, endocardium, myocardium, coronary circle, and conduction system. In the last decade many patients affected by autoimmune diseases have been treated with hematopoietic stem cell transplantation; the vast majority of these transplants have been autologous, and most have been within the context of phase I and II clinical trials; now, phase III trials are ongoing. Patients affected by autoimmune disease often have cardiac involvement which potentially puts them at higher risk from acute cardiotoxicity due to alkylating agents such as cyclophosphamide. The authors propose an algorithm for cardiac assessment before stem cell transplantation in order to identify those patients at highest risk, prior to administering any drug, to avoid further worsening of heart involvement and possible organ failure. A baseline assessment includes physical examinations, ECG to highlight arrhythmias and conduction abnormalities, chest X-ray to evaluate the presence of pericardial effusion and cardiothoracic ratio. A second-step evaluation includes echocardiography (which assesses the following parameters: left ventricular ejection fraction, diastolic function, tricuspid gradient, pulmonary acceleration time, right ventricular diameter and pericardial effusion, wall motion), Holter ECG that may highlight the presence of arrhythmias and biohumoral parameters such as brain natriuretic peptide and troponin I. If these parameters show abnormalities, a further step is required before transplantation. Cardiac catheterization allows to identify ischemic coronary diseases and pulmonary artery hypertension. Intensive monitoring with life card assessment before inclusion might establish ischemic coronary diseases or complex arrhythmias requiring pacing. Magnetic resonance imaging and single-photon emission computed tomography with dipyridamole are useful tools to evaluate the coronary flow. Treatment of ischemic coronary disease (assessment for revascularization), cardiac failure, pulmonary artery hypertension and arrhythmias constitutes the final step. The aim is to optimize cardiac status in order to allow intense immunosuppressive treatments.

AB - Heart involvement is a frequent cause of morbidity and mortality in autoimmune diseases. All cardiac structures can be involved: pericardium, endocardium, myocardium, coronary circle, and conduction system. In the last decade many patients affected by autoimmune diseases have been treated with hematopoietic stem cell transplantation; the vast majority of these transplants have been autologous, and most have been within the context of phase I and II clinical trials; now, phase III trials are ongoing. Patients affected by autoimmune disease often have cardiac involvement which potentially puts them at higher risk from acute cardiotoxicity due to alkylating agents such as cyclophosphamide. The authors propose an algorithm for cardiac assessment before stem cell transplantation in order to identify those patients at highest risk, prior to administering any drug, to avoid further worsening of heart involvement and possible organ failure. A baseline assessment includes physical examinations, ECG to highlight arrhythmias and conduction abnormalities, chest X-ray to evaluate the presence of pericardial effusion and cardiothoracic ratio. A second-step evaluation includes echocardiography (which assesses the following parameters: left ventricular ejection fraction, diastolic function, tricuspid gradient, pulmonary acceleration time, right ventricular diameter and pericardial effusion, wall motion), Holter ECG that may highlight the presence of arrhythmias and biohumoral parameters such as brain natriuretic peptide and troponin I. If these parameters show abnormalities, a further step is required before transplantation. Cardiac catheterization allows to identify ischemic coronary diseases and pulmonary artery hypertension. Intensive monitoring with life card assessment before inclusion might establish ischemic coronary diseases or complex arrhythmias requiring pacing. Magnetic resonance imaging and single-photon emission computed tomography with dipyridamole are useful tools to evaluate the coronary flow. Treatment of ischemic coronary disease (assessment for revascularization), cardiac failure, pulmonary artery hypertension and arrhythmias constitutes the final step. The aim is to optimize cardiac status in order to allow intense immunosuppressive treatments.

KW - Cardiac assessment

KW - Cardiotoxicity

KW - Immunosuppressive drugs

KW - Stem cell transplantation

KW - Systemic sclerosis

UR - http://www.scopus.com/inward/record.url?scp=33847400583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847400583&partnerID=8YFLogxK

U2 - 10.1007/s00059-007-2957-4

DO - 10.1007/s00059-007-2957-4

M3 - Article

C2 - 17323034

AN - SCOPUS:33847400583

VL - 32

SP - 43

EP - 50

JO - Herz

JF - Herz

SN - 0340-9937

IS - 1

ER -